| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
Natural flavonoid
|
|---|---|
| ln Vitro |
Penduletin (0-100 µg/mL, 48 hours) inhibits the proliferation of HepG2 and MCF-7 cell lines, with IC50 values of 25.8 and 6.4 µM, respectively [1]. Penduletin causes procaspase-3 to cleave in HepG2 and procaspase-3 and procaspase-8 to cleave in MCF-7 [1].
Penduletin exhibited anti-cancer activity in vitro. It showed inhibitory effects on the proliferation of various cancer cell lines. For example, it inhibited the viability of MCF-7 (breast cancer), A549 (lung cancer), HepG2 (liver cancer), and HCT-116 (colon cancer) cells. The IC50 values were 32.45 ± 2.1 μM (MCF-7), 28.67 ± 1.8 μM (A549), 25.32 ± 1.5 μM (HepG2), and 22.15 ± 1.2 μM (HCT-116), respectively. Additionally, penduletin induced apoptosis in these cancer cells, as evidenced by increased levels of cleaved caspase-3 and cleaved PARP, and decreased levels of Bcl-2, detected via western blot analysis. It also inhibited colony formation of cancer cells; the number of colonies was significantly reduced compared to the control group when treated with penduletin at concentrations of 10, 20, and 40 μM [2] |
| Enzyme Assay |
In silico studies were conducted to evaluate the binding affinity of penduletin with various cancer-related enzymes. Molecular docking was performed to assess the interaction between penduletin and targets such as EGFR, VEGFR-2, and PI3K. The binding energies were calculated, and the results showed that penduletin had strong binding affinity with these targets, with binding energies of -8.2 kcal/mol (EGFR), -7.8 kcal/mol (VEGFR-2), and -7.5 kcal/mol (PI3K), respectively. The binding mode analysis indicated that penduletin formed hydrogen bonds and hydrophobic interactions with key amino acid residues of the targets [2]
|
| Cell Assay |
For cell viability assay, cancer cells (MCF-7, A549, HepG2, HCT-116) were seeded in 96-well plates and incubated overnight. Then, different concentrations of penduletin (0-100 μM) were added, and the cells were incubated for 48 hours. After that, a cell viability reagent was added, and the absorbance was measured to calculate the cell viability and IC50 values.
For apoptosis assay, cancer cells were treated with penduletin at concentrations of 10, 20, and 40 μM for 48 hours. The cells were then collected, stained with annexin V-FITC and propidium iodide, and analyzed by flow cytometry to determine the apoptotic rate. For western blot analysis, cancer cells treated with penduletin were lysed, and the protein extracts were separated by SDS-PAGE, transferred to a membrane, and probed with specific antibodies against cleaved caspase-3, cleaved PARP, Bcl-2, and β-actin (as a loading control). The bands were visualized and quantified [2] |
| References |
|
| Additional Infomation |
Penduletin has been reported in Acanthospermum australe, Stylidocleome brachycarpa, and other organisms with data available.
|
| Molecular Formula |
C18H16O7
|
|---|---|
| Molecular Weight |
344.32
|
| Exact Mass |
344.089
|
| CAS # |
569-80-2
|
| PubChem CID |
5320462
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
595.1±50.0 °C at 760 mmHg
|
| Flash Point |
219.3±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.654
|
| LogP |
2.49
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
524
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C(=C2C(=C1)OC(=C(C2=O)OC)C3=CC=C(C=C3)O)O)OC
|
| InChi Key |
YSXFFLGRZJWNFM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O7/c1-22-12-8-11-13(14(20)17(12)23-2)15(21)18(24-3)16(25-11)9-4-6-10(19)7-5-9/h4-8,19-20H,1-3H3
|
| Chemical Name |
5-hydroxy-2-(4-hydroxyphenyl)-3,6,7-trimethoxychromen-4-one
|
| Synonyms |
Penduletin; 569-80-2; 5-hydroxy-2-(4-hydroxyphenyl)-3,6,7-trimethoxychromen-4-one; DTXSID00205437; 5-Hydroxy-2-(4-hydroxyphenyl)-3,6,7-trimethoxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5-hydroxy-2-(4-hydroxyphenyl)-3,6,7-trimethoxy-; FD7R8D6VZB; DTXCID00127928;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
